Skip to main content
. Author manuscript; available in PMC: 2015 May 15.
Published in final edited form as: J Nucl Med. 2010 Jan;51(1):121–129. doi: 10.2967/jnumed.109.066126

FIGURE 2.

FIGURE 2

In vitro characterization of PKI for direct imaging of Abl expression in tumors. (A) Radiotracer accumulation assay. In vitro uptake studies in cell lines K562 (overexpressing BCR-Abl) and BT-474 (devoid of Abl expression). (B) Inhibitory concentrations of 50% for SKI230 in cytotoxicity assay (WST-1 colorimetric assay). (C) Proof of SKI230 binding specificity using Anti-Abl siRNA in radiotracer accumulation assay: wild-type K562, (N1); K562 transfected with nonspecific siRNA control pool (N2); K562 transfected with 100 nM anti-Abl SiRNA (N3); and K562 transfected with 200 nM anti-Abl SiRNA (N4). (D) Western blot analysis of cells treated with radiolabeled compound. 1, Abl antibody Western blot anti–Human-cAbl; 2, protein standards; 3, A-431; 4, BT-474; 5 and 6, K562 (6, control for siRNA experiment); 7, K562 after 100 nM siRNA; and 8, K562 after 200nM siRNA.